The Hepzato Kit is the first FDA-approved liver-directed therapy for unresectable metastatic uveal melanoma, showing ...
The cumulative incidence of CRLM has declined, with survival gains mainly in synchronous cases, highlighting the need for ...
69 weeks (16 months) median hPFS in patients with uveal melanoma. 38 weeks (8.5 months) median hPFS in patients with cholangiocarcinoma. Importance of Repeated Treatments: The investigators’ approach ...
Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the ...
Relationship between immune-mediated adverse events and clinical outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors (ICI): A single institution experience. This is ...
When physicians prescribe systemic chemotherapy, they need to strike a careful balance: the dose needs be strong enough to kill cancer cells throughout the body but not so strong that it harms healthy ...
Please provide your email address to receive an email when new articles are posted on . Patients who underwent LT vs. chemotherapy-based multimodal therapy had significantly higher progression-free ...
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving ...
Advanced colon cancer is the leading cause of cancer-related death in young American men and the second highest worldwide. In the majority of these patients, as the cancer advances it metastasizes to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback